medigraphic.com
SPANISH

Salud Mental

ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2007, Number 1

<< Back Next >>

Salud Mental 2007; 30 (1)

Factores genéticos involucrados en la susceptibilidad para desarrollar enfermedad de Parkinson

Vidrio MH, Alonso VME, López LM
Full text How to cite this article

Language: Spanish
References: 72
Page: 16-24
PDF size: 80.55 Kb.


Key words:

Parkinson’s disease, genetics, polymorphisms, haplotype, genetic testing.

ABSTRACT

Parkinson’s disease (PD) is the main cause of parkinsonism (rigidity, resting tremor, bradykinesia and loss of postural reflexes). There is evidence highlighting the importance of the interaction between environmental factors and genetics on the pathogenesis of PD. The research about the role of genetics in Parkinson’s disease began with familial aggregation studies, which have shown that approximately 10-15% of patients with PD have a positive firstdegree family history of PD; this proportion is higher than a 1% found in controls.
Twins studies have found a larger concordance rate in monozygotic twins with early-onset PD (symptoms onset before 40 years of age). Nevertheless, dopaminergic functional studies in twins using PET (Positron Emission Tomography) with [18F]dopa have also shown a substantial role for inheritance in late-onset, sporadic PD. In one of these studies with clinically discordant twins (monozygotic and dizygotic), the concordance rate at baseline for subclinical striatal dopaminergic dysfunction was higher in monozygotic than dizygotic twin pairs (55% vs 18%, respectively) using functional neuroimaging criteria.
Nine loci have been so far identified and six genes inherited as a Mendelian fashion have been cloned.
Also, α-synuclein (PARK1) gene mutations were found to be pathogenic and responsible for a rare PD with an autosomal dominant inheritance in a large Greek-Italian family (the Contursi kindred). These findings have not been reproduced in patients with late-onset, sporadic PD. Mutations in the gene encoding for parkin (PARK2) are responsible for PD with an autosomal recessive trait and are relatively common in patients with early-onset PD.
Mutations in α-synuclein and parkin genes suggest that the dysfunction of the ubiquitine-proteasome system, that mediates degradation of proteins, plays an important role in the pathogenesis of PD. Ubiquitine is a key component of this system and is attached to the proteins by ubiquitine-ligases in order to mark them to be cleaved by the proteasome. The production of freeubiquitine involves a type of proteins called ubiquitine-hydrolases.
Mutations in a gene that encodes for one of these proteins, UCHL1, have been also involved in familial PD.
Cellular death models in PD have been centered in oxidative stress and excitoxicity mechanisms. Even though these mechanisms are still considered important, the models that highlight the abnormal aggregation of proteins and the failure of the ubiquitine proteolytic system are more consistent with available experimental data. The product of DJ-1 (PARK7) was recently involved in familial PD. This could protect dopaminergic neurons from damage due to oxidative stress as suggested by its structure similarity with the stress-induced bacterial chaperone (Hsp-31); it also could help in the appropriate folding of proteins. Other studies suggest DJ-1 mutations could contribute to the elevated levels of oxidative stress seen in PD.
Theories about the pathogenesis of PD have been developed independently of the findings in the genetics field. One particularly prominent model suggests that various mitochondrial alterations that produce failure in the production of cellular energy or elevated free radicals levels or both have an important role in PD pathogenesis, and some recent genetic findings support this theory. Mutations in the gene encoding for PINK1 (PARK6), a mitochondrial protein-kinase, have been found in some patients with familial PD.
Recently, a gene localized in PARK8 (LRRK2/dardarine) has been cloned. It is responsible for familial PD with autosomal dominant inheritance, typical age of onset and clinical findings similar to the ones found in idiopathic PD.
Association studies with candidate genes have discovered the influence of some polymorphisms on certain PD clinical features, at least in the populations studied. The relative risk and age of onset of PD, as well as the levodopa induced dyskinesia, are among these characteristics. Candidate genes were chosen because of their alleged role on the pathogenesis of PD. The major candidate genes studied so far are related to dopamine synthesis, transport and metabolism, xenobiotics and other neuronal toxins detoxification, mitochondrial metabolism, and also transcription factors and neurotrophic genes involved in the mesencephalic dopaminergic system development.
Of the susceptibility genes so far studied, only the MAO-B ›188 bp allele has shown a significant association in a meta-analysis.
Additionally, only six genes (DRD2, ND3, BNDF, α-synuclein, UCHL1 and Nurr-1) have shown important associations with PD in several studies and have fulfilled the criteria for their replication and meta-analysis.
These mixed results could be related to differences in sample size, ethnical background and methodology as to make it almost impossible to summarize independent studies. Other possible contributions are populations stratification, biologic credibility of the association between the gene and the phenotype and gene to gene interactions.
However, these mutations are not found in the great majority of patients with sporadic PD. In these patients, normal gene polymorphisms must confer susceptibility to PD, and certain, not-yetidentified, environmental factors must interact with them in order to produce clinically PD.
Parkinson’s disease (PD) is the main cause of parkinsonism (rigidity, resting tremor, bradykinesia and loss of postural reflexes). There is evidence highlighting the importance of the interaction between environmental factors and genetics on the pathogenesis of PD.
The research about the role of genetics in Parkinson’s disease began with familial aggregation studies, which have shown that approximately 10-15% of patients with PD have a positive firstdegree family history of PD; this proportion is higher than a 1% found in controls.
Twins studies have found a larger concordance rate in monozygotic twins with early-onset PD (symptoms onset before 40 years of age). Nevertheless, dopaminergic functional studies in twins using PET (Positron Emission Tomography) with [18F]dopa have also shown a substantial role for inheritance in late-onset, sporadic PD. In one of these studies with clinically discordant twins (monozygotic and dizygotic), the concordance rate at baseline for subclinical striatal dopaminergic dysfunction was higher in monozygotic than dizygotic twin pairs (55% vs 18%, respectively) using functional neuroimaging criteria.
Nine loci have been so far identified and six genes inherited as a Mendelian fashion have been cloned.
Also, α-synuclein (PARK1) gene mutations were found to be pathogenic and responsible for a rare PD with an autosomal dominant inheritance in a large Greek-Italian family (the Contursi kindred).
These findings have not been reproduced in patients with late-onset, sporadic PD. Mutations in the gene encoding for parkin (PARK2) are responsible for PD with an autosomal recessive trait and are relatively common in patients with early-onset PD.
Mutations in α-synuclein and parkin genes suggest that the dysfunction of the ubiquitine-proteasome system, that mediates degradation of proteins, plays an important role in the pathogenesis of PD. Ubiquitine is a key component of this system and is attached to the proteins by ubiquitine-ligases in order to mark them to be cleaved by the proteasome. The production of freeubiquitine involves a type of proteins called ubiquitine-hydrolases. Mutations in a gene that encodes for one of these proteins, UCHL1, have been also involved in familial PD.
Cellular death models in PD have been centered in oxidative stress and excitoxicity mechanisms. Even though these mechanisms are still considered important, the models that highlight the abnormal aggregation of proteins and the failure of the ubiquitine proteolytic system are more consistent with available experimental data. The product of DJ-1 (PARK7) was recently involved in familial PD. This could protect dopaminergic neurons from damage due to oxidative stress as suggested by its structure similarity with the stress-induced bacterial chaperone (Hsp-31); it also could help in the appropriate folding of proteins. Other studies suggest DJ-1 mutations could contribute to the elevated levels of oxidative stress seen in PD.
Theories about the pathogenesis of PD have been developed independently of the findings in the genetics field. One particularly prominent model suggests that various mitochondrial alterations that produce failure in the production of cellular energy or elevated free radicals levels or both have an important role in PD pathogenesis, and some recent genetic findings support this theory. Mutations in the gene encoding for PINK1 (PARK6), a mitochondrial protein-kinase, have been found in some patients with familial PD. Recently, a gene localized in PARK8 (LRRK2/dardarine) has been cloned. It is responsible for familial PD with autosomal dominant inheritance, typical age of onset and clinical findings similar to the ones found in idiopathic PD.
Association studies with candidate genes have discovered the influence of some polymorphisms on certain PD clinical features, at least in the populations studied. The relative risk and age of onset of PD, as well as the levodopa induced dyskinesia, are among these characteristics. Candidate genes were chosen because of their alleged role on the pathogenesis of PD. The major candidate genes studied so far are related to dopamine synthesis, transport and metabolism, xenobiotics and other neuronal toxins detoxification, mitochondrial metabolism, and also transcription factors and neurotrophic genes involved in the mesencephalic dopaminergic system development.
Of the susceptibility genes so far studied, only the MAO-B ›188 bp allele has shown a significant association in a meta-analysis. Additionally, only six genes (DRD2, ND3, BNDF, α-synuclein, UCHL1 and Nurr-1) have shown important associations with PD in several studies and have fulfilled the criteria for their replication and meta-analysis.
These mixed results could be related to differences in sample size, ethnical background and methodology as to make it almost impossible to summarize independent studies. Other possible contributions are populations stratification, biologic credibility of the association between the gene and the phenotype and gene to gene interactions.
However, these mutations are not found in the great majority of patients with sporadic PD. In these patients, normal gene polymorphisms must confer susceptibility to PD, and certain, not-yetidentified, environmental factors must interact with them in order to produce clinically PD.


REFERENCES

  1. AHARON-PERETZ J: Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Eng J Med, 351:1972-7, 2004.

  2. ALONSO M: Parkinson’s disease: A genetic study. Can J Neurol Sci, 13:248-51, 1986.

  3. BRADBURY J. α-Synuclein gene triplication discovered in Parkinson’s disease. Lancet Neurol, 2:715, 2003.

  4. BUERVENICH S, CARMINE A, GALTER D y cols.: A rare truncating mutation in ADH1C (G78Stop) shows significant association with Parkinson disease in a large international sample. Arch Neurol, 62:74-8, 2005.

  5. DUVOISIN RC: Role of genetics in the cause of Parkinson’s disease. Movement Disorders, 13(supl 1):7-12, 1998.

  6. ERIKSEN J, WSZOLEK Z, PETRUCELLI L: Molecular pathogenesis of Parkinson disease, Arch Neurol, 62:353-57, 2005.

  7. EUROPARKINSON study group: Familial aggregation of Parkinson’s disease, a population-based case-control study in Europe. Neurology, 52:1876-82, 1999.

  8. FARIN FM, HITOSIS Y, HALLAGAN SE, KUSHLEIKA J y cols.: Genetic polymorphisms of superoxide dismutase in Parkinson’s disease. Mov Disord, 16:705-707, 2001.

  9. FARRER M: A Chromosome 4p haplotype segregating with Parkinson’s disease and postural tremor. Hum Mol Genet, 8:81- 5, 1999.

  10. FARRER M, STONE J, MATA I: LRRK2 Mutations in Parkinson disease. Neurology, 65:738-40, 2005.

  11. FEANY M: New genetic insights into Parkinson’s disease. N Eng J Med, 351:1937-40, 2004.

  12. FUNAYAMA M: A new locus for Parkinson disease, PARK8 maps to chromosome 2p13. Nat Genet, 18:262-5, 1998.

  13. GASSER T: Genetics of Parkinson’s disease. Ann Neurol, 44 (Supl 1):S53-S57, 1998.

  14. GILGUN-SHERKI Y: Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson’s disease. Pharm Genomics J, 4:291-306, 2004.

  15. GISPERT S: Failure to find α-synuclein gene dosage changes in 190 patients with familial Parkinson’s disease. Arch Neurol, 62:96-98, 2005.

  16. GOUIDER-KHOUJA N: Clinical and genetic study of familial Parkinson’s disease in Tunisia. Neurology, 54:1603-09, 2000.

  17. HAUSER R: Parkinson disease. www.emedicine.com, junio 18, 2004.

  18. GOWERS W: Diseases of the Nervous System. P. Blakiston, Son & Co, Philadelphia, 1888.

  19. HICKS A, PETURSSON H, JONSSON T, STEFANSSON H y cols.: A susceptibility gene for late-onset idiopathic Parkinson’s disease succesfully mapped. Am J Hum Genet, 69:200, 2001.

  20. HUANG X, CHEN P, POOLE C: APOE-μ2 allele associated with higher prevalence of sporadic Parkinson disease. Neurol, 62: 2198-202, 2004.

  21. JARMAN P: Parkinson’s disease comes of age. BMJ, 318:1641-2, 1999.

  22. KACHERGUS J, MATA I, HULIHAN M y cols.: Identification of a novel LRRK2 mutation linked to autosomal parkinsonism: evidence of a common founder across European populations. Am J Hum Gen, 76:672-80, 2005.

  23. KITADA T: Mutations in the PARKIN gene cause autosomal recessive juvenil parkinsonism. Nature, 392:605-8, 1998.

  24. KRÜGER R, RIESS O: PARK3, ubiquitin hydrolase-l1 & other PD loci. En: Pulst S: Genetics of Movement Disorders. Academic Press, Londres, 2003.

  25. LANGSTON J, BALLARD PA y cols.: Chronic parkinsonism in humans due to a product of meperidine analog synthesis. Science, 219:979-980, 1983.

  26. LANGSTON J: Epidemiology versus genetics in Parkinson’s disease: progress in resolving an age-old debate. Ann Neurol, 44(Supl 1):S45-S52, 1998.

  27. LANGSTON J, GOLBE L, LEE S: PARK1 & α-Synuclein: a new era in Parkinson’s research. En: Pulst S: Genetics of Movement Disorders, Academic Press, Londres, 2003.

  28. Le COUTEUR DG, LEIGHTON PW, MCCANN SJ, POND S: Association of a polymorphism in the dopamine transporter gene with Parkinson’s disease. Mov Disord, 12:760-63, 1997.

  29. LE W, XU P, JANKOVIC J: Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet, 33:85-9, 2003.

  30. LEROY E: The ubiquitin pathway in Parkinson’s disease. Nature, 395:451-2, 1998.

  31. LI YJ, HAUSER MA, SCOTT WK y cols.: Apolipoprotein e controls the risk & age at onset of Parkinson disease. Neurology, 62:2005-9, 2004.

  32. LOHMUELLER KE, PEARCE CL, PIKE M, LANDER ES, HIRSCHHORN JN: Metaanalisys of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet, 33:177-82, 2003.

  33. LÜCKING C: Association between early-onset Parkinson’s disease and mutations in the PARKIN gene. N Eng J Med, 342:1560-7, 2000.

  34. MARAGANORE D, FARRER M, HARDY J: Case-control study of debrisoquine 4-hydroxylase, n-acetyltransferase 2, & apolipoprotein e gene polymorphisms in Parkinson’s disease. Mov Disord, 15:714-9, 2000.

  35. MARAGANORE D, DE ANDRADE M, LESNICK T: High resolution whole-genome association study of Parkinson disease. Am J Hum Genet, 77:685-93, 2005.

  36. MARDER K, LEVY G, LOUIS ED y cols.: Accuracy of family history data on parkinson’s disease. Neurology, 61:18-23, 2003.

  37. MARRAS C, TANNER C: Parkinson’s disease: genetic epidemiology & overview. En: Pulst S (ed.). Genetics of Movement Disorders. Academic Press, Londres, 2003.

  38. MATSUMINE H: A Microdeletion of D6S305 in a family of autosomal recessive juvenile parkinsonism (PARK2). Genomics, 49:143-6, 1998.

  39. McINERNEY-LEO A, HADLEY D, GWINN-HARDY K: Genetic testing in Parkinson’s disease. Mov Disord, 20:1-10, 2005.

  40. MIZUNO Y: Mitochondrial dysfunction in Parkinson’s disease. Ann Neurol, 44(Supl)1:S99-S109, 1998.

  41. MIZUNO Y, ASAKAWA S, SUZUKI T y cols.: Parkin mutations (PARK 2). En: Pulst S (ed.). Genetics of Movement Disorders, Academic Press, Londres, 2003.

  42. MORRIS HR: Genetics of Parkinson’s disease. Ann Med, 37:86-96, 2005.

  43. NISHIMURA M, KAJI R, OHTA M, MIZUTA I, KUNO S: Association between dopamine transporter gene polymorphism and susceptibility to Parkinson’s disease in Japan. Mov Disord, 17:831-32, 2002.

  44. NUSSBAUM RL: Alzheimer’s disease and Parkinson’s disease. N Eng J Med, 348:1356-64, 2003.

  45. PAISAN RUIZ, LANG A, KAWARAI T y cols.: LRRK2 gene in Parkinson’s disease, mutation analysis & case control association study. Neurology, 65:696-700, 2005.

  46. PANKRATZ N, NICHOLS W, UNIACKE S, RUDOLPH A, HALTER C y cols.: Genome screen to identify loci contributing to susceptibility for Parkinson’s disease. Am J Hum Genet, 69:535, 2001.

  47. PASSEY S: Gene mutation detected in parkinson’s disease. Lancet Neurol, 4:142-3, 2005.

  48. PHIMISTER E: Genomic cartography–presenting the Hap- Map. N Eng J Med, 17(353):1766-68, 2005.

  49. PICCINI P: The Role of inheritance in sporadic Parkinson’s disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol, 45:577-82, 1999.

  50. PLANTE-BORDENEUVE V, TAUSSIG D, THOMAS F, SAID G, WOOD NW y cols.: Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic PD: Evidence for association of a DRD2 allele. Neurology; 48:1589-93, 1997.

  51. POEWE W: The natural history of Parkinson’s disease. Ann Neurol. 44(Supl 1):S1-S9, 1998.

  52. POLYMEROPOULOS M: Autosomal dominant Parkinson’s disease and α-synuclein. Ann Neurol, 44(Supl 1):S63-S64, 1998.

  53. POLYMEROPOULOS MH: Mapping of a gene for Parkinson’s disease to chromosome 4q21-q23. Science, 274:1197-9, 1996.

  54. POLYMEROPOULOS MH: Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science, 276:2045-7, 1997.

  55. POSKANZER DC, SCHWAB RS: Cohort analysis of Parkinson’s syndrome, evidence for a single etiology related to subclinical infection about 1920. J Chron Dis, 16:961-73, 1963.

  56. PRIYADARSHI A: Environmental risks factors and Parkinson’s disease: a metaanalysis. Environ Res, 86:122-127, 2001.

  57. SAMII A: Parkinson’s disease. Lancet, 363:1783-93, 2004.

  58. SCHAPIRA A: Mitochondria in the etiology and pathogenesis of Parkinson’s disease. Ann Neurol, 44(Supl 1):S89-S98, 1998.

  59. SCHAPIRA A: Parkinson’s disease. BMJ, 318:311-314, 1999.

  60. SCOTT W: Complete genome screen in Parkinson disease: evidence for multiple genes. JAMA, 286:2239-44, 2001.

  61. SIDEROWF A: Update on Parkinson’s disease. Ann Intern Med, 138:651-658, 2003.

  62. SPILLANTINI MG: α-Synuclein in Lewy bodies. Nature, 388:839-40, 1997.

  63. STROOMBERGEN MCMJ, WARING RH: Determination of glutathione S-transferase μ and θ polymorphism in neurological disease. Hum Exp Toxicol, 18:141-45, 1999.

  64. SUNDBERG-INGELMAN M, DALY AK, NEBERT DW (eds.): CYPallele nomenclature homepage, http://www.ki.se/CYPalleles/ cyp2d6.htm

  65. SVEINBJÖRNSDÖTTIR S: Familial aggregation of Parkinson’s disease in Iceland. N Eng J Med, 343:1765-70, 2000.

  66. TAN EK: Variability and validity of polymorphism association studies in Parkinson’s disease. Neurology, 55:533-8, 2000.

  67. TANNER CM: Parkinson’s disease in twins: An etiologic study. JAMA, 281:341-6, 1999.

  68. THE INTERNATIONAL HAPMAP CONSORTIUM: A haplotype map of the human genome. Nature, 437:1299-320, 2005.

  69. VALENTE EM: Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science, 304:1158-60, 2004.

  70. VAN DUIJIN CM: PARK7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet, 69:629-34, 2001.

  71. WOOD N: Genetic risk factors in Parkinson’s disease. Ann Neurol, 44(Supl 1):S58-S62, 1998.

  72. ZAREPARSI S, CAMICIOLI R, SEXTON G y cols.: Age at onset of Parkinson disease & apolipoprotein E genotypes. Am J Med Gen, 107:156-161, 2001.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Salud Mental. 2007;30